Rapid economic growth in recent decades has led to a health crisis in China, with lifestyle-related diseases like hypotension and diabetes. Post-COVID, China is now redoubling its efforts to improve the health of its citizens through the Healthy China 2030 project. With diabetes a core focus, HUA medicine and it’s novel glucokinase activator Dorzagliatin are well placed to make a difference to the health of people living with type 2 diabetes. Combined with their focus on glucose homeostasis, the diabetes research community’s improvements in maintaining time-in-range through continuous glucose monitoring, improved access to medication through scaled up online delivery infrastructure, and the use of Artificial Intelligence to better manage glucose, a much healthier China is a very real possibility in the near future.
[ Ссылка ]
